Tag: fda regulatory science
-
FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug‑Induced Liver Injury
The U.S. Food and Drug Administration has taken an important step toward modernizing how new medicines are evaluated before they ever reach human testing. In early June 2026, the agency announced that it accepted the first Letter of Intent for an in silico, or computer‑based, drug development tool designed to help predict drug‑induced liver injury.…